 | Up a level |
Bahrami, Flora; Rossi, René Michel; De Nys, Katelijne; Joerger, Markus; Radenkovic, Milena Cukic; Defraeye, Thijs (2024). Implementing physics-based digital patient twins to tailor the switch of oral morphine to transdermal fentanyl patches based on patient physiology. European journal of pharmaceutical sciences, 195(106727), p. 106727. Elsevier 10.1016/j.ejps.2024.106727
Colombo, Ilaria; Koster, Kira-Lee; Holer, Lisa; Haefliger, Simon; Rabaglio, Manuela; Bastian, Sara; Schwitter, Michael; Eckhardt, Katrin; Hayoz, Stefanie; Mc Laughlin, Anna M; Kloft, Charlotte; Klose, Marian; Halbherr, Stefan; Baumgartner, Christian; Sessa, Cristiana; Stathis, Anastasios; Hess, Dagmar; Joerger, Markus (2024). TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). European journal of cancer, 201(113588), p. 113588. Elsevier 10.1016/j.ejca.2024.113588
Mark, Michael; Froesch, Patrizia; Gysel, Katrin; Rothschild, Sacha I; Addeo, Alfredo; Ackermann, Christoph J; Chiquet, Sabrina; Schneider, Martina; Ribi, Karin; Maranta, Angela Fischer; Bastian, Sara; von Moos, Roger; Joerger, Markus; Früh, Martin (2024). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. European journal of cancer, 200(113600), p. 113600. Elsevier 10.1016/j.ejca.2024.113600
Joerger, Markus; Hundsberger, Thomas; Haefliger, Simon; von Moos, Roger; Hottinger, Andreas F; Kaindl, Thomas; Engelhardt, Marc; Marszewska, Michalina; Lane, Heidi; Roth, Patrick; Stathis, Anastasios (2023). Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Investigational new drugs, 41(2), pp. 267-275. Springer 10.1007/s10637-023-01336-9
Nuñez, Nicolas Gonzalo; Berner, Fiamma; Friebel, Ekaterina; Unger, Susanne; Wyss, Nina; Gomez, Julia Martinez; Purde, Mette-Triin; Niederer, Rebekka; Porsch, Maximilian; Lichtensteiger, Christa; Kramer, Rafaela; Erdmann, Michael; Schmitt, Christina; Heinzerling, Lucie; Abdou, Marie-Therese; Karbach, Julia; Schadendorf, Dirk; Zimmer, Lisa; Ugurel, Selma; Klümper, Niklas; ... (2023). Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (N Y), 4(2), 113-129.e7. Cell Press 10.1016/j.medj.2022.12.007
Schmulenson, Eduard; Bovet, Cédric; Theurillat, Regula; Decosterd, Laurent Arthur; Largiadèr, Carlo R; Prost, Jean-Christophe; Csajka, Chantal; Bärtschi, Daniela; Guckenberger, Matthias; von Moos, Roger; Bastian, Sara; Joerger, Markus; Jaehde, Ulrich (2022). Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). British journal of clinical pharmacology, 88(12), pp. 5336-5347. Wiley-Blackwell 10.1111/bcp.15461
Addeo, Alfredo; Rothschild, Sacha I; Holer, Lisa; Schneider, Martina; Waibel, Christine; Haefliger, Simon; Mark, Michael; Fernandez, Eugenio; Mach, Nicolas; Mauti, Laetitia; Jermann, Philip M; Alborelli, Ilaria; Calgua, Byron; Savic-Prince, Spasenija; Joerger, Markus; Früh, Martin (2022). Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung cancer, 172, pp. 154-159. Elsevier 10.1016/j.lungcan.2022.08.016
Berner, Fiamma; Bomze, David; Lichtensteiger, Christa; Walter, Vincent; Niederer, Rebekka; Hasan Ali, Omar; Wyss, Nina; Bauer, Jens; Freudenmann, Lena Katharina; Marcu, Ana; Wolfschmitt, Eva-Maria; Haen, Sebastian; Gross, Thorben; Abdou, Marie-Therese; Diem, Stefan; Knöpfli, Stella; Sinnberg, Tobias; Hofmeister, Kathrin; Cheng, Hung-Wei; Toma, Marieta; ... (2022). Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Science immunology, 7(75), eabn9644. American Association for the Advancement of Science 10.1126/sciimmunol.abn9644
Purde, Mette‑Triin; Niederer, Rebekka; Wagner, ikolaus B.; Diem, Stefan; Berner, Fiamma; Hasan Ali, Omar; Hillmann, Dorothea; Bergamin, Irina; Joerger, Markus; Risch, Martin; Niederhauser, Christoph; Lenz, Tobias L.; Früh, Martin; Risch, Lorenz; Semela, David; Flatz, Lukas (2022). Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. Journal of cancer research and clinical oncology, 148(3), pp. 647-656. Springer 10.1007/s00432-021-03870-6
Rothschild, Sacha I; Zippelius, Alfred; Eboulet, Eric I; Savic Prince, Spasenija; Betticher, Daniel; Bettini, Adrienne; Früh, Martin; Joerger, Markus; Lardinois, Didier; Gelpke, Hans; Mauti, Laetitia A; Britschgi, Christian; Weder, Walter; Peters, Solange; Mark, Michael; Cathomas, Richard; Ochsenbein, Adrian F; Janthur, Wolf-Dieter; Waibel, Christine; Mach, Nicolas; ... (2021). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. Journal of clinical oncology, 39(26), pp. 2872-2880. American Society of Clinical Oncology 10.1200/JCO.21.00276
Süveg, Krisztian; Putora, Paul Martin; Joerger, Markus; Iseli, Thomas; Fischer, Galina Farina; Ammann, Karlheinz; Glatzer, Markus (2021). Radiotherapy for thymic epithelial tumours: a review. Translational lung cancer research, 10(4), pp. 2088-2100. AME Publishing 10.21037/tlcr-20-458
Herbrand, Amanda Katherina; Schmitt, Andreas M; Briel, Matthias; Ewald, Hannah; Goldkuhle, Marius; Diem, Stefan; Hoogkamer, Anouk; Joerger, Markus; Moffa, Giusi; Novak, Urban; Hemkens, Lars G; Kasenda, Benjamin (2021). Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. JAMA network open, 4(3), e210380. American Medical Association 10.1001/jamanetworkopen.2021.0380
Hamzic, Seid; Aebi, Stefan; Joerger, Markus; Montemurro, Michael; Ansari, Marc; Amstutz, Ursula; Largiadèr, Carlo (2020). Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. Swiss medical weekly, 150, w20375. EMH Media 10.4414/smw.2020.20375
Schaerer, Dominic; Froehlich, Tanja K.; Hamzic, Seid; Offer, Steven M.; Diasio, Robert B.; Joerger, Markus; Amstutz, Ursula; Largiadèr, Carlo R. (2020). A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies. Journal of personalized medicine, 10(4) MDPI 10.3390/jpm10040181
Hamzic, Seid; Kummer, Dominic; Froehlich, Tanja K.; Joerger, Markus; Aebi, Stefan; Palles, Claire; Thomlinson, Ian; Meulendijks, Didier; Schellens, Jan H M; García-González, Xandra; López-Fernández, Luis A; Amstutz, Ursula; Largiadèr, Carlo R. (2020). Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacological research, 152, p. 104594. Elsevier 10.1016/j.phrs.2019.104594
Hoemme, Alexander; Barth, Holger; Haschke, Manuel Martin; Krähenbühl, Stephan; Strasser, Florian; Lehner, Claudia; von Kameke, Alexander; Wälti, Thomas; Thürlimann, Beat; Früh, Martin; Driessen, Christoph; Joerger, Markus (2019). Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer chemotherapy and pharmacology, 83(4), pp. 763-774. Springer 10.1007/s00280-019-03783-9
Fässler, Mirjam; Diem, Stefan; Mangana, Joanna; Hasan Ali, Omar; Berner, Fiamma; Bomze, David; Ring, Sandra; Niederer, Rebekka; Del Carmen Gil Cruz, Cristina; Pérez Shibayama, Christian Ivan; Krolik, Michal; Siano, Marco; Joerger, Markus; Recher, Mike; Risch, Lorenz; Güsewell, Sabine; Risch, Martin; Speiser, Daniel E; Ludewig, Burkhard; Levesque, Mitchell P; ... (2019). Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. Journal for immunotherapy of cancer, 7(1), p. 50. BioMed Central 10.1186/s40425-019-0523-2
Herbrand, Amanda Katherina; Schmitt, Andreas Michael; Briel, Matthias; Diem, Stefan; Ewald, Hannah; Hoogkamer, Anouk; Joerger, Markus; Mc Cord, Kimberly Alba; Novak, Urban; Sricharoenchai, Sirintip; Hemkens, Lars G; Kasenda, Benjamin (2019). Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO open, 4(6), e000596. BMJ 10.1136/esmoopen-2019-000596
Parra-Guillen, Zinnia P; Berger, Peter B; Haschke, Manuel Martin; Donzelli, Massimiliano; Winogradova, Daria; Pfister, Bogumila; Früh, Martin; Gillessen, Silke; Krähenbühl, Stephan; Kloft, Charlotte; Joerger, Markus (2017). Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. Basic & clinical pharmacology & toxicology, 121(4), pp. 309-315. Wiley-Blackwell 10.1111/bcpt.12801
Baty, Florent; Joerger, Markus; Früh, Martin; Klingbiel, Dirk; Zappa, Francesco; Brutsche, Martin (2017). 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. Journal of translational medicine, 15(1), p. 66. BioMed Central 10.1186/s12967-017-1174-z
Driessen, Christoph; Kraus, Marianne; Joerger, Markus; Rosing, Hilde; Bader, Jürgen; Hitz, Felicitas; Berset, Catherine; Xyrafas, Alexandros; Hawle, Hanne; Berthod, Gregoire; Overkleeft, Hermann S; Sessa, Cristiana; Huitema, Alwin; Pabst, Thomas; von Moos, Roger; Hess, Dagmar; Mey, Ulrich J M (2016). Treatment with the HIV protease inhibitor Nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica - the hematology journal, 101(3), pp. 346-355. Ferrata-Storti Foundation 10.3324/haematol.2015.135780
Kummer, Dominic; Fröhlich, Tanja; Joerger, Markus; Aebi, Stefan; Sistonen, Johanna; Amstutz, Ursula; Largiadèr, Carlo Rodolfo (2015). Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. Pharmacogenomics, 16(12), pp. 1367-1377. Future Medicine 10.2217/pgs.15.81
Amstutz, Ursula; Offer, Steven M; Sistonen, Johanna; Joerger, Markus; Diasio, Robert B; Largiadèr, Carlo Rodolfo (2015). Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clinical cancer research, 21(9), pp. 2038-2044. American Association for Cancer Research 10.1158/1078-0432.CCR-14-2817
Fröhlich, Tanja; Amstutz, Ursula; Aebi, Stefan; Joerger, Markus; Largiadèr, Carlo Rodolfo (2015). Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. International journal of cancer, 136(3), pp. 730-739. Wiley-Blackwell 10.1002/ijc.29025
Sistonen, Johanna; Büchel, Barbara; Fröhlich, Tanja; Kummer, Dominic; Fontana, Stefano; Joerger, Markus; van Kuilenburg, André B P; Largiadèr, Carlo Rodolfo (2014). Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics, 15(13), pp. 1653-1666. Future Medicine 10.2217/pgs.14.126
Büchel, Barbara; Sistonen, Johanna; Joerger, Markus; Aebi, Yolanda; Schürch, Stefan; Largiadèr, Carlo Rodolfo (2013). Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients. Clinical chemistry and laboratory medicine, 51(8), pp. 1681-1688. De Gruyter 10.1515/cclm-2012-0641
Joerger, Markus; Wilkins, Justin; Fagagnini, Stefania; Baldinger, Reto; Brenneisen, Rudolf; Schneider, Ursula; Goldman, Bea; Weber, Markus (2012). Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis. Drug metabolism letters, 6(2), pp. 102-8. Sharjah: Bentham Science Publishers
Joerger, Markus; Ferreri, Andrés J M; Krähenbühl, Stephan; Schellens, Jan H M; Cerny, Thomas; Zucca, Emanuele; Huitema, Alwin D R (2012). Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. British journal of clinical pharmacology, 73(2), pp. 240-7. Oxford: Wiley-Blackwell 10.1111/j.1365-2125.2011.04084.x
Herbrand, Amanda; Schmitt, Andreas; Briel, Matthias; Diem, Stefan; Ewald, Hannah; Hoogkamer, Anouk; Joerger, Markus; Mc Cord, Kimberly; Novak, Urban; Sricharoenchai, Sirintip; Hemkens, Lars; Kasenda, Benjamin (29 July 2019). Contrasting Evidence to Reimbursement Reality for Off-label use 1 (OLU) of Drug Treatments in Cancer Care – Rationale and Design of 2 the CEIT-OLU-project (medRxiv). Cold Spring Harbor Laboratory 10.1101/19003152
